Michael Schmidt

Shares of Rain Oncology Inc (NASDAQ: RAIN) recovered in early trading on Tuesday, after having plummeted on disappointing cancer study data. Here are some key analyst takeaways from the company’s decision to halt studies for its lead candidate as a treatment for dedifferentiated (DD)...

Arvinas Inc (NASDAQ: ARVN) shares have been on a tear ever since the company issued a platform update in late October. The Analyst Guggenheim Securities analyst Michael Schmidt initiated coverage of Arvinas with a Buy rating and $50 price target.  The Thesis Arvinas, a small-cap, early...

Puma Biotechnology Inc (NASDAQ: PBYI) released positive top-line results for its lead drug candidate PB272, or Nerlynx, which is being evaluated for treating HER2+ metastatic breast cancer patients who have failed two or more prior lines of HER2+ directed treatments. Nerlynx along with capecitabine...

Shares of bluebird bio Inc (NASDAQ: BLUE) are up 360 percent over the last two years, but Leerink said the stock’s losing steam. The Rating Leerink analyst Michael Schmidt downgraded Bluebird from Outperform to Market Perform and increased the price target from $162 to $194. The Thesis...

Leerink downgraded shares of Exelixis, Inc. (NASDAQ: EXEL) and lowered its price target, citing an $8.6 billion diluted market cap. The firm thinks the consensus estimates now adequately reflect the commercial potential for Cabometyx in renal cell carcinoma, and the valuation implied additional...

Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, or NSCLC, candidate sitravatinib. The company said the data will be presented at the IASLC 2017...

Following Array Biopharma Inc (NASDAQ: ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink thinks it will require a sizeable commercial effort to capture share in a market that has plateaued...

Shares of Agios Pharmaceuticals Inc (NASDAQ: AGIO) plunged more than 20 percent as it discontinued the development of a blood disorder study after FDA opined that the drug no longer had an appropriate risk-benefit ratio. Agios was developing AG-519, its "backup" pyruvate kinase-R (PKR...

Leerink’s Michael Schmidt noted that despite the recent outperformance, Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) shares were still trading at a discount to its commercial-stage oncology biotech peers, although the company’s top line was expected to grow at a 35 percent CAGR during...

On Monday, Leerink issued a report previewing the American Society of Hematology annual meeting, which will be held from December 5 to December 8. Leerink believes that this meeting will have meaningful clinical updates for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Juno Therapeutics Inc (...